The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
T antigen is bound to a host protein in SY40-transformed cells
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“was named p53 in 1979 because its molecular weight was shown to be approximately 53 kilodalton (kDa) in SDS polyacrylamide gel electrophoresis analysis15”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, S. W. (1975) · The Journal of Immunology · doi:10.4049/jimmunol.115.6.1617 · Cited by 2,915
Complete nucleotide sequence of SV40 DNA
Fiers, W., Contreras, R., Haegeman, G., Rogiers, R., Van de Voorde, A., Van Heuverswyn, H., Van Herreweghe, J., Volckaert, G., & Ysebaert, M. (1978) · Nature · doi:10.1038/273113a0 · Cited by 1,010
Reddy, V. B., Thimmappaya, B., Dhar, R., Subramanian, K. N., Zain, B. S., Pan, J., Ghosh, P. K., Celma, M. L., & Weissman, S. M. (1978) · Science · doi:10.1126/science.205947 · Cited by 919
Spliced early mRNAs of simian virus 40
Berk, A. J., & Sharp, P. A. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.3.1274 · Cited by 776
Simian Virus 40 Deoxyribonucleic Acid Synthesis: the Viral Replicon
Tegtmeyer, P. (1972) · Journal of Virology · doi:10.1128/jvi.10.4.591-598.1972 · Cited by 578
Regulation of tumor antigen synthesis by simain virus 40 gene A
Tegtmeyer, P., Schwartz, M., Collins, J. K., & Rundell, K. (1975) · Journal of Virology · doi:10.1128/jvi.16.1.168-178.1975 · Cited by 426
THE SMALL SUBUNIT OF HL-A ANTIGENS IS ß2-MICROGLOBULIN
Grey, H. M., Kubo, R. T., Colon, S. M., Poulik, M. D., Cresswell, P., Springer, T. A., Turner, M., & Strominger, J. L. (1973) · The Journal of Experimental Medicine · doi:10.1084/jem.138.6.1608 · Cited by 367
Mutants of SV40 with an altered small t protein are reduced in their ability to transform cells
Sleigh, M. (1978) · Cell · doi:10.1016/0092-8674(78)90303-3 · Cited by 275
Cited by
Items 101–200 of 206
The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis
Levine, A., Perry, M., Chang, A., Silver, A., Dittmer, D., Wu, M., & Welsh, D. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.76 · Cited by 422
A complex barcode underlies the heterogeneous response of p53 to stress
Murray-Zmijewski, F., Slee, E. A., & Lu, X. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2451 · Cited by 420
The transcriptional targets of p53 in apoptosis control
Yu, J., & Zhang, L. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.189 · Cited by 420
p53-Dependent apoptosis pathways
(2001) · Advances in Cancer Research · doi:10.1016/s0065-230x(01)82002-9 · Cited by 418
Wolf, D., & Rotter, V (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.3.790 · Cited by 410
TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade
Leroy, B., Anderson, M., & Soussi, T. (2014) · Human Mutation · doi:10.1002/humu.22552 · Cited by 408
Viruses associated with human cancer
McLaughlin-Drubin, M. E., & Munger, K. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2007.12.005 · Cited by 406
Lee, S., Elenbaas, B., Levine, A., & Griffith, J. (1995) · Cell · doi:10.1016/s0092-8674(05)80006-6 · Cited by 405
p53 modifications: exquisite decorations of the powerful guardian
Liu, Y., Tavana, O., & Gu, W. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz060 · Cited by 392
Pan, H., & Griep, A. E. (1994) · Genes & Development · doi:10.1101/gad.8.11.1285 · Cited by 404
Barr, A. R., Cooper, S., Heldt, F. S., Butera, F., Stoy, H., Mansfeld, J., Novák, B., & Bakal, C. (2017) · Nature Communications · doi:10.1038/ncomms14728 · Cited by 403
Lavigueur, A., Maltby, V, Mock, D., Rossant, J., Pawson, T., & Bernstein, A. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.9.3982 · Cited by 394
TP53 Mutations in Nonsmall Cell Lung Cancer
Mogi, A., & Kuwano, H. (2011) · BioMed Research International · doi:10.1155/2011/583929 · Cited by 388
Cellular factors required for multiple stages of SV40 DNA replication in vitro.
Fairman, M. P., & Stillman, B. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb02933.x · Cited by 386
Uncovering the role of p53 splice variants in human malignancy: a clinical perspective
Bourdon, J.-C., Surget, S., & Khoury, M. P. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s53876 · Cited by 382
Gurney, E. G., Harrison, R. O., & Fenno, J. (1980) · Journal of Virology · doi:10.1128/jvi.34.3.752-763.1980 · Cited by 377
Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus
Berk, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1209040 · Cited by 377
Santhanam, U., Ray, A., & Sehgal, P. B. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.17.7605 · Cited by 375
Shuda, M., Kwun, H. J., Feng, H., Chang, Y., & Moore, P. S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46323 · Cited by 374
Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity
O'Shea, C. C., Johnson, L., Bagus, B., Choi, S., Nicholas, C., Shen, A., Boyle, L., Pandey, K., Soria, C., Kunich, J., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.11.012 · Cited by 372
Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease
Butel, J. S. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.405 · Cited by 371
The genome of human papovavirus BKV
Seif, I., Khoury, G., & Dhar, R. (1979) · Cell · doi:10.1016/0092-8674(79)90209-5 · Cited by 370
Hemann, M. T., & Lowe, S. W. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401962 · Cited by 370
Association of adenovirus early-region 1A proteins with cellular polypeptides.
Harlow, E., Whyte, P., Franza, B. R., & Schley, C. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.5.1579 · Cited by 369
Cellular transformation by SV40 large T antigen: interaction with host proteins
Ali, S. H., & DeCaprio, J. A. (2001) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0342 · Cited by 367
Bargonetti, J., Friedman, P. N., Kern, S. E., Vogelstein, B., & Prives, C. (1991) · Cell · doi:10.1016/0092-8674(91)90560-l · Cited by 367
Functional inactivation but not structural mutation of p53 causes liver cancer
Ueda, H., Ullrich, S. J., Gangemi, J. D., Kappel, C. A., Ngo, L., Feitelson, M. A., & Jay, G. (1995) · Nature Genetics · doi:10.1038/ng0195-41 · Cited by 367
Targeting the MDM2-p53 Interaction for Cancer Therapy
Shangary, S., & Wang, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5136 · Cited by 366
Mietz, J. A., Unger, T., Huibregtse, J. M., & Howley, P. M. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05608.x · Cited by 365
Molecular mechanisms of human T-cell leukemia/lymphotropic virus type I infection
Franchini, G. (1995) · Blood · doi:10.1182/blood.v86.10.3619.bloodjournal86103619 · Cited by 360
Kress, M., May, E., Cassingena, R., & May, P. (1979) · Journal of Virology · doi:10.1128/jvi.31.2.472-483.1979 · Cited by 359
Li-Fraumeni syndrome – a molecular and clinical review
Varley, J., Evans, D., & Birch, J. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.328 · Cited by 358
Shaulsky, G., Goldfinger, N., Ben-Ze'ev, A., & Rotter, V (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.12.6565 · Cited by 356
Biofilm Forming Lactobacillus: New Challenges for the Development of Probiotics
Salas-Jara, M., Ilabaca, A., Vega, M., & García, A. (2016) · Microorganisms · doi:10.3390/microorganisms4030035 · Cited by 353
Brugge, J. S., Erikson, E., & Erikson, R. L. (1981) · Cell · doi:10.1016/0092-8674(81)90055-6 · Cited by 346
A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas
Soragni, A., Janzen, D. M., Johnson, L. M., Lindgren, A. G., Thai-Quynh Nguyen, A., Tiourin, E., Soriaga, A. B., Lu, J., Jiang, L., Faull, K. F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.002 · Cited by 341
“p53 is a tumor suppressor of paramount importance and the most frequently mutated protein in human cancers (Lane and Crawford, 1979; Levine and Oren, 2009; Linzer and Levine, 1979).”
BackgroundHuman p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2.
Bischoff, J. R., Friedman, P. N., Marshak, D. R., Prives, C., & Beach, D. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.12.4766 · Cited by 342
Li, Y., Graham, C., Lacy, S., Duncan, A. M., & Whyte, P. (1993) · Genes & Development · doi:10.1101/gad.7.12a.2366 · Cited by 337
Autophagy: Regulation and role in development
Hale, A. N., Ledbetter, D. J., Gawriluk, T. R., & Rucker, III (2013) · Autophagy · doi:10.4161/auto.24273 · Cited by 336
Donehower, L. A., & Bradley, A. (1993) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(93)90004-v · Cited by 333
Characterization of the human p53 gene.
Lamb, P., & Crawford, L. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.5.1379 · Cited by 327
Self-citationTumor-Suppressor Functions of the TP53 Pathway
Aubrey, B. J., Strasser, A., & Kelly, G. L. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026062 · Cited by 327
Vogelstein, B. (1990) · Nature · doi:10.1038/348681a0 · Cited by 324
Positive selection of candidate tumor-suppressor genes by subtractive hybridization.
Lee, S. W., Tomasetto, C., & Sager, R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.7.2825 · Cited by 319
Advances in Chemical Carcinogenesis: A Historical Review and Prospective
Loeb, L. A., & Harris, C. C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2852 · Cited by 317
Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines.
Cheng, J., & Haas, M. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.10.5502 · Cited by 316
Singh, N., Piskorz, A. M., Bosse, T., Jimenez‐Linan, M., Rous, B., Brenton, J. D., Gilks, C. B., & Köbel, M. (2020) · The Journal of Pathology · doi:10.1002/path.5375 · Cited by 316
Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53.
Reich, N. C., Oren, M., & Levine, A. J. (1983) · Molecular and Cellular Biology · doi:10.1128/mcb.3.12.2143 · Cited by 312
The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth.
Finlay, C. A. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.1.301 · Cited by 311
Zambetti, G. P., Bargonetti, J., Walker, K., Prives, C., & Levine, A. J. (1992) · Genes & Development · doi:10.1101/gad.6.7.1143 · Cited by 311
EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins.
Szekely, L., Selivanova, G., Magnusson, K. P., Klein, G., & Wiman, K. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.12.5455 · Cited by 309
History of protein–protein interactions: From egg‐white to complex networks
Braun, P., & Gingras, A. (2012) · PROTEOMICS · doi:10.1002/pmic.201100563 · Cited by 308
Prevalence and Spectrum of Germline Mutations of the p53 Gene among Patients with Sarcoma
Toguchida, J., Yamaguchi, T., Dayton, S. H., Beaughamp, R. L., Herrera, G. E., Ishizaki, K., Yamamuro, T., Meyers, P. A., Little, J. B., Sasaki, M. S., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262001 · Cited by 307
Alternative splicing in cancer: implications for biology and therapy
Chen, J., & Weiss, W. A. (2015) · Oncogene · doi:10.1038/onc.2013.570 · Cited by 304
Dyson, N., Buchkovich, K., Whyte, P., & Harlow, E. (1989) · Cell · doi:10.1016/0092-8674(89)90839-8 · Cited by 303
TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance
Silwal-Pandit, L., Vollan, H. K. M., Chin, S.-F., Rueda, O. M., McKinney, S., Osako, T., Quigley, D. A., Kristensen, V. N., Aparicio, S., Børresen-Dale, A.-L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2943 · Cited by 303
Howes, K. A., Ransom, N., Papermaster, D. S., Lasudry, J. G., Albert, D. M., & Windle, J. J. (1994) · Genes & Development · doi:10.1101/gad.8.11.1300 · Cited by 303
Human TAFII31 protein is a transcriptional coactivator of the p53 protein.
Lu, H., & Levine, A. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.5154 · Cited by 301
Regulation of the Human hsp70 Promoter by p53
Agoff, S. N., Hou, J., Linzer, D. I., & Wu, B. (1993) · Science · doi:10.1126/science.8418500 · Cited by 292
Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene.
Matlashewski, G., Lamb, P., Pim, D., Peacock, J., Crawford, L., & Benchimol, S. (1984) · The EMBO Journal · doi:10.1002/j.1460-2075.1984.tb02287.x · Cited by 299
Self-citationThe molecular basis for cell cycle delays following ionizing radiation: a review
Maity, A., McKenna, W. G., & Muschel, R. J. (1994) · Radiotherapy and Oncology · doi:10.1016/0167-8140(94)90408-1 · Cited by 294
Harris, C. C. (1996) · Carcinogenesis · doi:10.1093/carcin/17.6.1187 · Cited by 285
Cellular Transformation and Malignancy Induced by ras Require c-jun
Johnson, R., Spiegelman, B., Hanahan, D., & Wisdom, R. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.8.4504 · Cited by 282
Zimmermann, H., Degenkolbe, R., Bernard, H.-U., & O’Connor, M. J. (1999) · Journal of Virology · doi:10.1128/jvi.73.8.6209-6219.1999 · Cited by 282
Chaabane, W., User, S. D., El-Gazzah, M., Jaksik, R., Sajjadi, E., Rzeszowska-Wolny, J., & Łos, M. J. (2013) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-012-0205-y · Cited by 282
An immunoaffinity purification procedure for sv40 large t antigen
Simanis, V., & Lane, D. P. (1985) · Virology · doi:10.1016/0042-6822(85)90308-3 · Cited by 282
Self-citationp53 and DNA polymerase α compete for binding to SV40 T antigen
Gannon, J. V., & Lane, D. P. (1987) · Nature · doi:10.1038/329456a0 · Cited by 282
Self-citationControl of the G2/M Transition
Stark, G. R., & Taylor, W. R. (2006) · Molecular Biotechnology · doi:10.1385/mb:32:3:227 · Cited by 279
A variation in the structure of the protein-coding region of the human p53 gene
Buchman, V. L., Chumakov, P. M., Ninkina, N. N., Samarina, O. P., & Georgiev, G. P. (1988) · Gene · doi:10.1016/0378-1119(88)90196-5 · Cited by 278
To die or not to die: how does p53 decide?
Slee, E. A., O'Connor, D. J., & Lu, X. (2004) · Oncogene · doi:10.1038/sj.onc.1207516 · Cited by 278
The p53 tumour suppressor protein is phosphorylated at serine 389 by casein kinase II.
Meek, D. W., Simon, S., Kikkawa, U., & Eckhart, W. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07524.x · Cited by 277
The growth arrest-specific gene, gas1, is involved in growth suppression
Del Sal, G. (1992) · Cell · doi:10.1016/0092-8674(92)90429-g · Cited by 275
Lechner, M. S., Mack, D. H., Finicle, A. B., Crook, T., Vousden, K. H., & Laimins, L. A. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05375.x · Cited by 273
Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway.
Chen, C. Y., Oliner, J. D., Zhan, Q., Fornace, A. J., Vogelstein, B., & Kastan, M. B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.7.2684 · Cited by 271
Mechanisms of p53 loss in human sarcomas.
Mulligan, L. M., Matlashewski, G. J., Scrable, H. J., & Cavenee, W. K. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.15.5863 · Cited by 269
Mutant p53: an oncogenic transcription factor
Strano, S., Dell'Orso, S., Di Agostino, S., Fontemaggi, G., Sacchi, A., & Blandino, G. (2007) · Oncogene · doi:10.1038/sj.onc.1210296 · Cited by 269
Monoclonal antibody analysis of p53 expression in normal and transformed cells
Yewdell, J. W., Gannon, J. V., & Lane, D. P. (1986) · Journal of Virology · doi:10.1128/jvi.59.2.444-452.1986 · Cited by 264
Self-citationT Antigens of Simian Virus 40: Molecular Chaperones for Viral Replication and Tumorigenesis
Sullivan, C. S., & Pipas, J. M. (2002) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.66.2.179-202.2002 · Cited by 258
Smoking, p53 Mutation, and Lung Cancer
Gibbons, D. L., Byers, L. A., & Kurie, J. M. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0539 · Cited by 255
Mercer, W. E., Nelson, D., DeLeo, A. B., Old, L. J., & Baserga, R. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.20.6309 · Cited by 255
Hughes, P. E., Alexi, T., Walton, M., Williams, C. E., Dragunow, M., G. Clark, R., & Gluckman, P. D. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00057-4 · Cited by 253
The p53 family: guardians of maternal reproduction
Levine, A. J., Tomasini, R., McKeon, F. D., Mak, T. W., & Melino, G. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3086 · Cited by 252
Huibregtse, J. M., Scheffner, M., & Howley, P. M. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.2.775 · Cited by 233
Yaar, M., Eller, M. S., & Gilchrest, B. A. (2002) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1046/j.1523-1747.2002.19636.x · Cited by 233
Stressin’ Sestrins take an aging fight
Budanov, A. V., Lee, J. H., & Karin, M. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000097 · Cited by 208
The Isoforms of the p53 Protein
Khoury, M. P., & Bourdon, J.-C. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000927 · Cited by 191
Inhibition of p53 DNA binding by human papillomavirus E6 proteins
Lechner, M. S., & Laimins, L. A. (1994) · Journal of Virology · doi:10.1128/jvi.68.7.4262-4273.1994 · Cited by 195
Huibregtse, J. M., Scheffner, M., & Howley, P. M. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.8.4918 · Cited by 182
Demers, G. W., Foster, S. A., Halbert, C. L., & Galloway, D. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.10.4382 · Cited by 172
The many faces of p53: something for everyone
Levine, A. J. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz026 · Cited by 163
p53 engages the cGAS/STING cytosolic DNA sensing pathway for tumor suppression
Ghosh, M., Saha, S., Li, J., Montrose, D. C., & Martinez, L. A. (2023) · Molecular Cell · doi:10.1016/j.molcel.2022.12.023 · Cited by 166
Brown, D. R., Thomas, C. A., & Palit Deb, S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.9.2513 · Cited by 148
Borellini, F., & Glazer, R. I. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53046-5 · Cited by 147
Loss of p53 protein in human papillomavirus type 16 E6-immortalized human mammary epithelial cells
Band, V, De Caprio, J. A., Delmolino, L., Kulesa, V, & Sager, R. (1991) · Journal of Virology · doi:10.1128/jvi.65.12.6671-6676.1991 · Cited by 145
Structural analysis of the interaction between Hsp90 and the tumor suppressor protein p53
Hagn, F., Lagleder, S., Retzlaff, M., Rohrberg, J., Demmer, O., Richter, K., Buchner, J., & Kessler, H. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2114 · Cited by 127
Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3
LeBron, C., Chen, L., Gilkes, D. M., & Chen, J. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601032 · Cited by 122
P53 and The Immune Response: 40 Years of Exploration—A Plan for the Future
Levine, A. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020541 · Cited by 97
Targeting Therapies for the p53 Protein in Cancer Treatments
Levine, A. J. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055455 · Cited by 84
Overexpression of the MDM2 Oncogene in Leukemia and Lymphoma
Watanabe, T., Ichikawa, A., Saito, H., & Hotta, T. (1996) · Leukemia & Lymphoma · doi:10.3109/10428199609093436 · Cited by 80
Regulation of Metabolic Activity by p53
Flöter, J., Kaymak, I., & Schulze, A. (2017) · Metabolites · doi:10.3390/metabo7020021 · Cited by 81
Metadata
- Authors
- LANE, D. P., & CRAWFORD, L. V.
- Venue
- Nature
- Published
- 1979-03
- Volume
- 278
- Issue
- 5701
- Pages
- 261-263
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2018385269
- Cited by
- 2,394
- References
- 8
- FWCI
- 30.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.